Advertisement

Head and Neck Pathology

, Volume 11, Issue 4, pp 427–441 | Cite as

Oral Pyoderma Gangrenosum: Diagnosis, Treatment and Challenges: A Systematic Review

  • Caroline Bissonnette
  • Adel Kauzman
  • Gisele N. MainvilleEmail author
Original Paper

Abstract

Pyoderma gangrenosum (PG) is a distinctive ulcerative skin disorder of unknown etiology, associated with an underlying systemic disease in up to 70% of cases. The condition is characterized by the appearance of one or more necrotic ulcers with a ragged undermined violaceous border and surrounding erythema. Lesions are often initiated by minor trauma. The condition can affect any anatomical site, however the head and neck are rarely involved. Although the oral cavity is subject to recurrent minor trauma through everyday activities such as mastication and oral hygiene, as well as during dental treatment, oral lesions appear to be extremely rare. In an effort to provide a detailed explanation of the oral manifestations of PG, a systematic search was conducted using medical databases. A total of 20 cases of PG with oral involvement were reported in the English and French literature. The objectives of this article are to present the pertinent diagnostic criteria and to discuss the differential diagnosis and therapeutic modalities.

Keywords

Pyoderma gangrenosum Persistent oral ulcer Oral Oropharyngeal 

Notes

Compliance with Ethical Standards

Conflict of interest

Caroline Bissonnette declares that she has no conflict of interest. Adel Kauzman declares that he has no conflict of interest. Gisele N. Mainville declares that she has no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Powell FC, Schroeter AL, Su WP, Perry HO. Pyoderma gangrenosum: a review of 86 patients. Q J Med. 1985;55(217):173–86.PubMedGoogle Scholar
  2. 2.
    Su WP, Davis MD, Weenig RH, Powell FC, Perry HO. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol. 2004;43(11):790–800. doi: 10.1111/j.1365-4632.2004.02128.x.CrossRefPubMedGoogle Scholar
  3. 3.
    von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137(6):1000–5.CrossRefGoogle Scholar
  4. 4.
    Kiran RP, O’Brien-Ermlich B, Achkar JP, Fazio VW, Delaney CP. Management of peristomal Pyoderma gangrenosum. Dis Colon Rectum. 2005;48(7):1397–403. doi: 10.1007/s10350-004-0944-x.CrossRefPubMedGoogle Scholar
  5. 5.
    Setterfield JF, Shirlaw PJ, Challacombe SJ, Black MM. Pyoderma gangrenosum associated with severe oropharyngeal involvement and IgA paraproteinaemia. Br J Dermatol. 2001;144(2):393–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Lazarus GS, Goldsmith LA, Rocklin RE, Pinals RS, de Buisseret JP, David JR. Pyoderma gangrenosum, altered delayed hypersensitivity and polyarthritis. Arch Dermatol. 1972;105(1):46–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34(3):395–409 (quiz 10–2).CrossRefPubMedGoogle Scholar
  8. 8.
    Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of Pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015;73(4):691–8. doi: 10.1016/j.jaad.2015.06.021.CrossRefPubMedGoogle Scholar
  9. 9.
    Bhat RM. Pyoderma gangrenosum: An update. Indian Dermatol Online J. 2012;3(1):7–13. doi: 10.4103/2229-5178.93482.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yco MS, Warnock GR, Cruickshank JC, Burnett JR. Pyoderma gangrenosum involving the head and neck. Laryngoscope. 1988;98(7):765–8. doi: 10.1288/00005537-198807000-00016.CrossRefPubMedGoogle Scholar
  11. 11.
    Al Ghazal P, Dissemond J. Multilocular Pyoderma gangrenosum after uterus resection. Chirurg. 2012;83(3):254–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Basu MK, Asquith P. Oral manifestations of inflammatory bowel disease. Clin Gastroenterol. 1980;9(2):307–21.PubMedGoogle Scholar
  13. 13.
    Drinda S, Oelzner P, Codina Canet C, Kaatz M, Wolf G, Hein G. Fatal outcome of Pyoderma gangrenosum with multiple organ involvement and partially responding to Infliximab. Cent Eur J Med. 2006;1(3):306–12. doi: 10.2478/s11536-006-0024-9.Google Scholar
  14. 14.
    Margoles JS, Wenger J. Stomal ulceration associated with Pyoderma gangrenosum and chronic ulcerative colitis. Report of two cases. Gastroenterology. 1961;41:594–8.PubMedGoogle Scholar
  15. 15.
    Tsuboi H. Case of Pyoderma gangrenosum showing oral and genital ulcers, misdiagnosed as Behcet’s disease at first medical examination. J Dermatol. 2008;35(5):289–92. doi: 10.1111/j.1346-8138.2008.00468.x.CrossRefPubMedGoogle Scholar
  16. 16.
    Goulden V, Bond L, Highet AS. Pyoderma gangrenosum associated with paroxysmal nocturnal haemoglobinuria. Clin Exp Dermatol. 1994;19(3):271–3.CrossRefPubMedGoogle Scholar
  17. 17.
    Hernandez-Martin A, Arias-Palomo D, Hermida G, Gutierrez-Ortega MC, Ramirez-Herrera M, Rodriguez-Vegas M, et al. Oral Pyoderma gangrenosum. Br J Dermatol. 2003;149(3):663–4.CrossRefPubMedGoogle Scholar
  18. 18.
    Park HJ, Han BG, Kim YC, Cinn YW. Recalcitrant oral Pyoderma gangrenosum in a child responsive to cyclosporine. J Dermatol. 2003;30(8):612–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Buckley C, Bayoumi AH, Sarkany I. Pyoderma gangrenosum with severe pharyngeal ulceration. J R Soc Med. 1990;83(9):590–1.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Poiraud C, Gagey-Caron V, Barbarot S, Durant C, Ayari S, Stalder JF. Cutaneous, mucosal and systemic Pyoderma gangrenosum. Ann Dermatol Venereol. 2010;137(3):212–5. doi: 10.1016/j.annder.2010.01.007.CrossRefPubMedGoogle Scholar
  21. 21.
    Curi MM, Cardoso CL, Koga DH, Zardetto C, Araújo SR. Pyoderma gangrenosum affecting the mouth. Open J Stomatol. 2013;3(2):4.CrossRefGoogle Scholar
  22. 22.
    Verma S, Field S, Murphy G. Photoletter to the editor: oral ulceration in Pyoderma gangrenosum. J Dermatol Case Rep. 2011;5(2):34–5. doi: 10.3315/jdcr.2011.1070.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Chariatte N, Lysitsa S, Lombardi T, Samson J. Pyoderma gangrenosum (2ème partie): manifestations buccales et présentation d’un cas. Med Buccale Chir Buccale. 2011;17(3):225–35.CrossRefGoogle Scholar
  24. 24.
    Paramkusam G, Meduri V, Gangeshetty N. Pyoderma gangrenosum with oral involvement: case report and review of the literature. Int J Oral Sci. 2010;2(2):111–6. doi: 10.4248/ijos10032.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Bertram-Callens A, Machet L, Vaillant L, Camenen I, Lorette G. Buccal and ocular localizations of Pyoderma gangrenosum in Vaquez’s disease. Ann Dermatol Venereol. 1991;118(9):611–4.PubMedGoogle Scholar
  26. 26.
    Kennedy KS, Prendergast ML, Sooy CD. Pyoderma gangrenosum of the oral cavity, nose, and larynx. Otolaryngol Head Neck Surg. 1987;97(5):487–90.CrossRefPubMedGoogle Scholar
  27. 27.
    Yusuf H, Ead RD. Pyoderma gangrenosum with involvement of the tongue. Br J Oral Maxillofac Surg. 1985;23(4):247–50.CrossRefPubMedGoogle Scholar
  28. 28.
    Zampeli VA, Lippert U, Nikolakis G, Makrantonaki E, Tzellos TG, Krause U, et al. Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. Treatment with infliximab. J Dermatol Case Rep. 2015;9(3):62–6. doi: 10.3315/jdcr.2015.1206.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Al Attas KM, Ahsan MK, Buraik M, Gamal AM, Hannani HY. Fatal pyoderma gangrenosum in a patient with inflammatory bowel disease and hypogonadotropic hypogonadism: case report. J Saudi Soc Dermatol Dermatol Surg. 2013;17(2):4.CrossRefGoogle Scholar
  30. 30.
    Isomura I, Miyawaki S, Morita A. Pyoderma gangrenosum associated with nasal septal perforation, oropharyngeal ulcers and IgA paraproteinemia. J Dermatol. 2005;32(3):193–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Kaomongkolgit R, Subbalekha K, Sawangarun W, Thongprasom K. Pyoderma gangrenosum-like oral ulcerations in an elderly patient. Gerodontology. 2015;32(4):309–13. doi: 10.1111/ger.12158.CrossRefPubMedGoogle Scholar
  32. 32.
    Siddiqui S, Fiorillo M, Tismenetsky M, Spinnell M. Isolated oral Pyoderma gangrenosum following proctocolectomy. Am J Gastroenterol. 2012;107:S517–S8.Google Scholar
  33. 33.
    Callen JP, Taylor WB. Pyoderma gangrenosum: a literature review. Cutis. 1978;21(1):61–4.PubMedGoogle Scholar
  34. 34.
    Philpott JA Jr, Goltz RW, Park RK. Pyoderma gangrenosum, rheumatoid arthritis, and diabetes mellitus. Arch Dermatol. 1966;94(6):732–8.CrossRefPubMedGoogle Scholar
  35. 35.
    DeFilippis EM, Feldman SR, Huang WW. The genetics of Pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol. 2015;172(6):1487–97. doi: 10.1111/bjd.13493.CrossRefPubMedGoogle Scholar
  36. 36.
    Tolkachjov SN, Fahy AS, Wetter DA, Brough KR, Bridges AG, Davis MD, et al. Postoperative Pyoderma gangrenosum (PG): the Mayo Clinic experience of 20 years from 1994 through 2014. J Am Acad Dermatol. 2015;73(4):615–22. doi: 10.1016/j.jaad.2015.06.054.CrossRefPubMedGoogle Scholar
  37. 37.
    Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH): a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66(3):409–15. doi: 10.1016/j.jaad.2010.12.025.CrossRefPubMedGoogle Scholar
  38. 38.
    Hong JB, Su YN, Chiu HC. Pyogenic arthritis, Pyoderma gangrenosum, and acne syndrome (PAPA syndrome): report of a sporadic case without an identifiable mutation in the CD2BP1 gene. J Am Acad Dermatol. 2009;61(3):533–5. doi: 10.1016/j.jaad.2008.11.017.CrossRefPubMedGoogle Scholar
  39. 39.
    Calderon-Castrat X, Bancalari-Diaz D, Roman-Curto C, Romo-Melgar A, Amoros-Cerdan D, L AA-M, et al. PSTPIP1 gene mutation in a Pyoderma gangrenosum, acne and suppurative hidradenitis (PASH) syndrome. Br J Dermatol. 2015. doi: 10.1111/bjd.14383.Google Scholar
  40. 40.
    Marzano AV, Trevisan V, Gattorno M, Ceccherini I, De Simone C, Crosti C. Pyogenic arthritis, Pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013;149(6):762–4. doi: 10.1001/jamadermatol.2013.2907.CrossRefPubMedGoogle Scholar
  41. 41.
    Neville BW, Damm DD, Allen CM, Chi AC. Oral and maxillofacial pathology. 4th ed. St. Louis: W. B. Saunders; 2016.Google Scholar
  42. 42.
    Hirshberg A, Amariglio N, Akrish S, Yahalom R, Rosenbaum H, Okon E, et al. Traumatic ulcerative granuloma with stromal eosinophilia: a reactive lesion of the oral mucosa. Am J Clin Pathol. 2006;126(4):522–9. doi: 10.1309/afha406gbt0n2y64.CrossRefPubMedGoogle Scholar
  43. 43.
    Sirois DA, Miller AS, Harwick RD, Vonderheid EC. Oral manifestations of cutaneous T cell lymphoma. A report of eight cases. Oral Surg Oral Med Oral Pathol. 1993;75(6):700–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Comfere NI, Macaron NC, Gibson LE. Cutaneous manifestations of Wegener’s granulomatosis: a clinicopathologic study of 17 patients and correlation to antineutrophil cytoplasmic antibody status. J Cutan Pathol. 2007;34(10):739–47. doi: 10.1111/j.1600-0560.2006.00699.x.CrossRefPubMedGoogle Scholar
  45. 45.
    Wang WC, Chen JY, Chen YK, Lin LM. Tuberculosis of the head and neck: a review of 20 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(3):381–6. doi: 10.1016/j.tripleo.2008.11.002.CrossRefPubMedGoogle Scholar
  46. 46.
    Wallach D, Vignon-Pennamen MD. Pyoderma gangrenosum and Sweet syndrome: the prototypic neutrophilic dermatoses. Br J Dermatol. 2015. doi: 10.1111/bjd.13955.PubMedGoogle Scholar
  47. 47.
    Amouri M, Masmoudi A, Ammar M, Boudaya S, Khabir A, Boudawara T, et al. Sweet’s syndrome: a retrospective study of 90 cases from a tertiary care center. Int J Dermatol. 2016. doi: 10.1111/ijd.13232.PubMedGoogle Scholar
  48. 48.
    The International Criteria for Behcet’s Disease (ICBD). A collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47. doi: 10.1111/jdv.12107.CrossRefGoogle Scholar
  49. 49.
    Gibson LE, Daoud MS, Muller SA, Perry HO. Malignant pyodermas revisited. Mayo Clin Proc. 1997;72(8):734–6. doi: 10.1016/s0025-6196(11)63593-3.CrossRefPubMedGoogle Scholar
  50. 50.
    Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for Pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53(2):273–83. doi: 10.1016/j.jaad.2004.10.006.CrossRefPubMedGoogle Scholar
  51. 51.
    Zuo KJ, Fung E, Tredget EE, Lin AN. A systematic review of post-surgical Pyoderma gangrenosum: identification of risk factors and proposed management strategy. J Plast Reconstr Aesthet Surg. 2015;68(3):295–303. doi: 10.1016/j.bjps.2014.12.036.CrossRefPubMedGoogle Scholar
  52. 52.
    Marzano AV, Alberti-Violetti S, Crippa R, Angiero F, Tadini G, Crosti C. Pyoderma gangrenosum with severe cutaneous and oral involvement. Eur J Dermatol. 2013;23(2):257–8. doi: 10.1684/ejd.2013.1968.PubMedGoogle Scholar
  53. 53.
    Snyder RA. Pyoderma gangrenosum involving the head and neck. Arch Dermatol. 1986;122(3):295–302.CrossRefPubMedGoogle Scholar
  54. 54.
    Baloch BK, Baloch SK, Kumar S, Mansoor F, Jawad A. Orogenital ulcers of Pyoderma gangrenosum resembling sexually transmitted disease. J Coll Physicians Surg Pak. 2014;24 Suppl 3:S207–8.PubMedGoogle Scholar
  55. 55.
    Ormerod AD, Thomas KS, Craig FE, Mitchell E, Greenlaw N, Norrie J, et al. Comparison of the two most commonly used treatments for Pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. Bmj. 2015;350:h2958. doi: 10.1136/bmj.h2958.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982–92. doi: 10.1097/mib.0000000000000392.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of Pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505–9. doi: 10.1136/gut.2005.074815.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Agarwal A, Andrews JM. Systematic review: IBD-associated Pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther. 2013;38(6):563–72. doi: 10.1111/apt.12431.CrossRefPubMedGoogle Scholar
  59. 59.
    Ambooken B, Khader A, Muhammed K, Rajan U, Snigdha O. Malignant Pyoderma gangrenosum eroding the parotid gland successfully treated with dexamethasone pulse therapy. Int J Dermatol. 2014;53(12):1536–8. doi: 10.1111/ijd.12519.CrossRefPubMedGoogle Scholar
  60. 60.
    Ye MJ, Ye JM. Pyoderma gangrenosum: a review of clinical features and outcomes of 23 cases requiring inpatient management. Dermatol Res Pract. 2014;2014:461467. doi: 10.1155/2014/461467.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010;62(4):646–54. doi: 10.1016/j.jaad.2009.05.030.CrossRefPubMedGoogle Scholar
  62. 62.
    Brunsting LA, Goeckerman WH, O’Leary PA. Pyoderma (echthyma) gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syphilol. 1930;22(4):655–80. doi: 10.1001/archderm.1930.01440160053009.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Caroline Bissonnette
    • 1
  • Adel Kauzman
    • 2
  • Gisele N. Mainville
    • 2
    Email author
  1. 1.Resident, Multidisciplinary Residency Program, Faculty of DentistryUniversite de MontrealMontrealCanada
  2. 2.Oral and Maxillofacial Pathologist, Department of Stomatology, Faculty of DentistryUniversite de MontrealMontrealCanada

Personalised recommendations